MX2024011654A - Formulaciones que comprenden melfalan flufenamida y ciclodextrina - Google Patents

Formulaciones que comprenden melfalan flufenamida y ciclodextrina

Info

Publication number
MX2024011654A
MX2024011654A MX2024011654A MX2024011654A MX2024011654A MX 2024011654 A MX2024011654 A MX 2024011654A MX 2024011654 A MX2024011654 A MX 2024011654A MX 2024011654 A MX2024011654 A MX 2024011654A MX 2024011654 A MX2024011654 A MX 2024011654A
Authority
MX
Mexico
Prior art keywords
cyclodextrin
flufenamide
formulations including
including melphalan
melphalan
Prior art date
Application number
MX2024011654A
Other languages
English (en)
Spanish (es)
Inventor
Fredrik Lehmann
Peter Teodorovic
Kristin Hammer
Rune Ringom
Original Assignee
Oncopeptides Innovation Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncopeptides Innovation Ab filed Critical Oncopeptides Innovation Ab
Publication of MX2024011654A publication Critical patent/MX2024011654A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024011654A 2022-03-24 2024-09-23 Formulaciones que comprenden melfalan flufenamida y ciclodextrina MX2024011654A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2204171.9A GB202204171D0 (en) 2022-03-24 2022-03-24 Novel formulations
PCT/EP2023/057729 WO2023180565A1 (en) 2022-03-24 2023-03-24 Formulations comprising melphalan flufenamide and cyclodextrin

Publications (1)

Publication Number Publication Date
MX2024011654A true MX2024011654A (es) 2025-01-09

Family

ID=81449463

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011654A MX2024011654A (es) 2022-03-24 2024-09-23 Formulaciones que comprenden melfalan flufenamida y ciclodextrina

Country Status (11)

Country Link
US (1) US20250205155A1 (https=)
EP (1) EP4499049A1 (https=)
JP (1) JP2025510725A (https=)
KR (1) KR20240161664A (https=)
CN (1) CN119053323A (https=)
AU (1) AU2023241241A1 (https=)
CA (1) CA3245985A1 (https=)
GB (1) GB202204171D0 (https=)
IL (1) IL315551A (https=)
MX (1) MX2024011654A (https=)
WO (1) WO2023180565A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025233915A1 (en) * 2024-05-10 2025-11-13 Allgenesis Biotherapeutics Inc. Use of an agonist of formyl peptide receptors 1 and 2 for treating ocular inflammatory diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002202D0 (sv) 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
DK2701720T3 (en) 2011-04-28 2017-10-09 Oncopeptides Ab Lyophilized preparation with cytotoxic dipeptides
SMT202000058T1 (it) 2012-10-26 2020-03-13 Oncopeptides Ab Preparazioni liofilizzate di melfalan flufenammide
GB201507903D0 (en) 2015-05-08 2015-06-24 Oncopeptides Ab Process for preparation of nitrogen mustard derivatives
US12152087B2 (en) 2018-10-18 2024-11-26 Oncopeptides Innovation Ab Deuterated melflufen compounds
GB201905477D0 (en) 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations

Also Published As

Publication number Publication date
AU2023241241A1 (en) 2024-10-31
CA3245985A1 (en) 2023-09-28
WO2023180565A1 (en) 2023-09-28
EP4499049A1 (en) 2025-02-05
US20250205155A1 (en) 2025-06-26
CN119053323A (zh) 2024-11-29
JP2025510725A (ja) 2025-04-15
KR20240161664A (ko) 2024-11-12
GB202204171D0 (en) 2022-05-11
IL315551A (en) 2024-11-01

Similar Documents

Publication Publication Date Title
CR20220281A (es) Derivados de pirazolilo útiles como agentes anti-cancerígenos
SA521422143B1 (ar) 15-pgdh مثبط
BR112022007867A2 (pt) Degradadores de pequena molécula de helios e métodos de uso
BR112021021857A2 (pt) Métodos para formação de complexos de inclusão com derivados de beta-ciclodextrina hidrofílicos e composições dos mesmos
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
MX392213B (es) Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano.
BRPI0509863A (pt) liberação de fármaco para fundo de olho
JOP20210004A1 (ar) عوامل تحلّل مستقبلات الإستروجين الانتقائية
BR112023019435A2 (pt) Inibidores de nek7
MX2021006969A (es) Ligante peptidico.
BR112021011325A2 (pt) Derivados de rapamicina
AR117652A1 (es) Composiciones farmacéuticas que comprenden conjugados de anticuerpo anti-191p4d12 y fármaco y métodos de usarlas
BR112023015272A2 (pt) Formulações farmacêuticas de centanafadina e métodos de fabricação e uso das mesmas
MX2020003993A (es) Derivados de bencimidazol y sus usos.
WO2022106902A3 (en) Benzenesulfonamide derivatives and uses thereof
PE20250835A1 (es) Composiciones y uso de la tirzepatida
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
MX2024011654A (es) Formulaciones que comprenden melfalan flufenamida y ciclodextrina
WO2023064612A3 (en) Pharmaceutical compositions for delivery of viral antigens and related methods
CL2023000491A1 (es) Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020).
CL2024002379A1 (es) Composición farmacéutica y que comprende derivados de difenildiazol métodos de uso
CL2024001073A1 (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
PH12022551810A1 (en) Protein-antiviral compound conjugates
MX2025013861A (es) Compuestos anti virus de la inmunodeficiencia humana (vih)
PH12021551396A1 (en) Active ester derivatives of testosterone, compositions and uses thereof